Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 4/20 | 0.66 |
| ▸ | MAP1LC3B | Q9GZQ8 | 7/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | IL1B | P01584 | 1/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30996464 | 1.00 | STAT3 (0.66) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL21294451 | 1.00 | STAT3 (0.66) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL21303980 | 1.00 | STAT3 (0.66) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL21304422 | 0.99 | STAT3 (0.65) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL28970883 | 0.96 | STAT3 (0.65) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL30437920 | 0.96 | STAT3 (0.65) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL22773798 | 0.94 | STAT3 (0.67) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL20933049 | 0.94 | STAT3 (0.67) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL22788954 | 0.94 | STAT3 (0.67) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL22789078 | 0.94 | STAT3 (0.67) | STAT3MAP1LC3BCRBNIKZF3IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110615779-B | Process for preparing lenalidomide derivatives | 上海科技大学 | 2023-03-24 | — | — | CN | claimed |
| CN-110615779-A | Process for preparing lenalidomide derivatives | 上海科技大学 | 2019-12-27 | — | — | CN | claimed |
| EP-3762381-B1 | BIVALENT AGENTS COMPRISING A SERINE THREONINE KINASE (AKT) LIGAND COVALENTLY LINKED TO A DEGRADATION/DISRUPTION MOIETY FOR THE TREATMENT OF CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-01 | — | — | US | disclosed |
| US-11472799-B2 | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-10-18 | — | — | US | disclosed |
| US-11472799-B2 | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-10-18 | — | — | US | disclosed |
| EP-3762381-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-112154146-A | Serine threonine kinase (AKT) degradation/disruption compounds and methods of use | 西奈山伊坎医学院 | 2020-12-29 | — | — | CN | disclosed |
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2019173516-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | MKNK1, MKNK2, MTOR | STAT3 998/4885MAP1LC3B 1163/4885CRBN 527/4885 |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | MKNK1, MKNK2, MTOR | STAT3 998/4885MAP1LC3B 1163/4885CRBN 527/4885 |
| US-11472799-B2 | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use | MKNK1, MKNK2, MTOR | STAT3 998/4885MAP1LC3B 1163/4885CRBN 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.